MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
About the study
The purpose of this study is to evaluate the effects, good and/or bad, of MEK162 and imatinib on the patient and on Gastrointestinal Stromal Tumor (GIST).
Funding Source - FDA OOPD, Array/Pfizer
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Gastrointestinal Stromal Tumor (GIST)
Age (in years)
18+
Phase
PHASE1/PHASE2
Participants needed
75
Est. Completion Date
Nov 30, 2025
Treatment type
INTERVENTIONAL
Sponsor
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov identifier
NCT01991379
Study number
13162
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?